| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| 500mg |
Purity: ≥98%
| Targets |
The mechanism of action of NSC601980 is not explicitly defined in the available literature, but it is associated with antitumor activity and the ability to inhibit cell proliferation. The compound has shown activity in yeast screening, suggesting that it may affect conserved cellular processes related to cell cycle regulation or DNA metabolism. Its primary target is not specified, but its activity in yeast and human cancer cell lines indicates it may interact with fundamental cellular pathways.
|
|---|---|
| ln Vitro |
NSC601980 inhibits cell proliferation in human cancer cell lines. It has been shown to inhibit cell proliferation in COLO 205 and HT29 cell lines with Log GI50 values of -6.6 and -6.9, respectively. These Log GI50 values indicate potent antiproliferative activity. The compound's activity was identified through yeast screening, which serves as a primary assay for detecting antitumor activity.
|
| ln Vivo |
In vivo activity data for NSC601980 are not detailed in the available sources. The compound's primary characterization comes from in vitro yeast screening and human cancer cell line proliferation assays. Specific in vivo efficacy studies (e.g., xenograft models) have not been described in the available literature. The compound's activity in yeast and cancer cell lines suggests potential for in vivo efficacy, but such data are not available.
|
| Enzyme Assay |
The yeast screening assay used to identify the antitumor activity of NSC601980 involves treating yeast cells with the compound and assessing growth inhibition. The specific protocol for this assay is not detailed. For human cancer cell line assays, cells are seeded in 96-well plates and treated with varying concentrations of the compound for 72 hours. Cell proliferation is measured using a colorimetric assay such as MTT or SRB. The GI50 (concentration causing 50% growth inhibition) is calculated from the dose-response curve.
|
| Cell Assay |
Cells (e.g., COLO 205 colon cancer or HT29 colorectal cancer cells) are cultured in appropriate medium supplemented with fetal bovine serum and antibiotics. Cells are seeded in 96-well plates at a density of 5,000-10,000 cells per well and allowed to attach overnight. The next day, cells are treated with a dilution series of the compound (e.g., 0.01-100 μM) for 72 hours. After treatment, cell viability is assessed using a standard assay (e.g., MTT, WST-1, or SRB). Absorbance is measured at the appropriate wavelength, and the GI50 value is calculated using nonlinear regression analysis. Log GI50 values are reported as -6.6 for COLO 205 and -6.9 for HT29 cells.
|
| Animal Protocol |
Specific in vivo animal experiment protocols for NSC601980 are not detailed in the available sources. The compound has not been described in the context of xenograft models or other in vivo efficacy studies. Given its in vitro antiproliferative activity, it may be evaluated in standard xenograft models in future studies, but such data are not currently available.
|
| ADME/Pharmacokinetics |
Specific pharmacokinetic data for NSC601980 are not provided in the available sources. The compound is structurally related to NSC 601980 analog (CAS# 91757-46-9), which has a molecular weight of 250.30. Standard pharmacokinetic studies would typically involve administering the compound to rodents and measuring plasma concentrations over time using LC-MS/MS to determine key PK parameters, but such data are not currently available.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for NSC601980 are not provided in the available sources. As a research compound, it is intended for laboratory use only and is not approved for human therapeutic applications. The compound is available with a purity of ≥98%. Standard safety precautions should be followed when handling this compound.
|
| References |
N/A
|
| Additional Infomation |
NSC601980 demonstrates antitumor activity in yeast screening experiments and inhibits cell proliferation in COLO 205 and HT29 cancer cell lines with Log GI50 values of -6.6 and -6.9, respectively. The compound is used in cancer research to study cell proliferation inhibition. It is structurally related to NSC 601980 analog (CAS# 91757-46-9). The compound is supplied for research purposes with a purity of ≥98%.
|
| Molecular Formula |
C₂₇H₂₉CL₂N₇O₂S
|
|---|---|
| Molecular Weight |
586.54
|
| Appearance |
Typically exists as solid at room temperature
|
| SMILES |
O=C(NCC1=CC=C(S(C2=CC(F)=CC(F)=C2)(=O)=O)C=C1)C3=CN4C(C=C3)=NC=C4.Cl
|
| Synonyms |
NSC 601980; NSC601980; NSC-601980
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.7049 mL | 8.5246 mL | 17.0491 mL | |
| 5 mM | 0.3410 mL | 1.7049 mL | 3.4098 mL | |
| 10 mM | 0.1705 mL | 0.8525 mL | 1.7049 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA